LORELEI trial of letrozole and taselisib for ER positive breast cancer
11 Sep 2017
LORELEI trial of letrozole and taselisib for ER positive breast cancer
Nivolumab and ipilimumab for metastatic kidney cancer
Biological insight in new drug combinations
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection
The role of tumour marker testing in early diagnosis
The METRIC trial of trametinib, five years on
Patient perceptions of chemotherapy side effects differ over time and treatment
Treatment choices in thyroid cancer
Clinical advances in treating colorectal cancer
Impact of licensing and reimbursement discrepancies on cancer care in Europe and Canada
New strategies in melanoma care
RANGE trial of ramucirumab for urothelial cancer